556results about How to "Increased activation" patented technology

Antibodies which block the binding of human Programmed Death Receptor 1 (hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. Dynamic stimulation through ramped cycling of electrical stimulation, stimulation frequency alteration, and / or duty cycle variance can produce therapeutic benefits.

A method for the treatment of obesity or other disorders, by wireless electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by wirelessly stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using a wireless electrode inductively coupled with a radiofrequency field. The source of radiofrequency energy may be internal or external to the patient. This nerve activation can result in reduced food intake and increased energy expenditure.

A rehabilitation device, comprising a movement element capable of controlling at least one motion parameter of a portion of a patient; a brain monitor which generates a signal indicative of brain activity; and circuitry including a memory having stored therein rehabilitation information and which inter-relates said signal and movement of said movement element as part of a rehabilitation process which utilizes said rehabilitation information.

Embodiments of the invention include methods and compositions related to improved cells encoding a chimeric antigen receptor that is specific for two or more antigens. In certain aspects the receptor encompasses two or more non-identical antigen recognition domains. The antigens are tumor antigens, in particular embodiments.

A method for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. Dynamic stimulation through ramped cycling of electrical stimulation, stimulation frequency alteration, and / or duty cycle variance can produce therapeutic benefits.

The present invention is a method for forming super steep doping profiles in MOS transistor structures. The method comprises forming a carbon containing layer (110) beneath the gate dielectric (50) and source and drain regions (80) of a MOS transistor. The carbon containing layer (110) will prevent the diffusion of dopants into the region (40) directly beneath the gate dielectric layer (50).

Apparatus and method for growth of non-p-type GaN layers over p-type GaN layers. Embodiments include multi-junction LED film stacks, multi-junction LED devices paired into units and multi-junction LED arrays of the paired units. Epitaxial growths of p-type and non-p-type material layers are split between epitaxial chambers clustered onto a single platform to reduce p-type dopant cross-contamination. Arrayed multi-junction LED devices provide improved packing density and reduced blinking during AC operation.

The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and / or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.

Antibodies which block the binding of human Programmed Death Receptor 1(hPD-1) to its ligands (hPD-L1 or hPD-L2) and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune response through the PD-I pathway is also disclosed.

A method of controlled p-type conductivity in (Al,In,Ga,B)N semiconductor crystals. Examples include {10 11} GaN films deposited on {100} MgAl2O4 spinel substrate miscut in the <011> direction. Mg atoms may be intentionally incorporated in the growing semipolar nitride thin film to introduce available electronic states in the band structure of the semiconductor crystal, resulting in p-type conductivity. Other impurity atoms, such as Zn or C, which result in a similar introduction of suitable electronic states, may also be used.

A device for increasing the range of motion of a patient's knee joint comprising of a longitudinal track frame, having a sitting platform at one end and a movable leg and foot platform at the other end, driven back and forth by a foot actuation mechanism in a flexion-extension motion, linearly along the longitudinal track by an electronically controlled motor in accordance with user defined settings and operable in a passive, active or resistive mode in either a supine or sitting position.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.

A method for treating an ailment of a patient using at least one electrode implanted within a spinal column of the patient at a T4-T6 spinal nerve level. The method comprises increasing an activation threshold of a side-effect exhibiting neural structure relative to the activation threshold of a dorsal column (DC) nerve fiber of the patient, and applying electrical stimulation energy to the DC nerve fiber via the at least one electrode while the activation threshold of the neural structure is increased, thereby treating the ailment while minimizing stimulation of the neural structure. Another method comprises applying electrical stimulation energy to the spinal column of the patient via the plurality of electrodes, thereby generating a medio-lateral electrical field relative to the spinal column of the patient and treating the ailment.

A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.

Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as therapeutic methods utilizing the polyclonal antibody. Finally, the invention also pertains to a method for screening for useful VH and VL pairs useful when preparing the polyclonal antibody.

The present invention provides methods of preventing, treating or ameliorating one or more symptoms of disorders in which modulation of a subject's immune system is beneficial utilizing a lymphoid tissue inducing agent and an immunomodulatory agent. In particular, the present invention provides methods of preventing, treating or ameliorating a proliferative disorder, an infectious disease, a cardiovascular disease, an autoimmune disorder, or an inflammatory disorder or one or more symptoms thereof comprising administering to a subject in need thereof one or more lymphoid tissue inducing agents and one or immunomodulatory agents. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to proliferative disorders, infectious diseases, cardiovascular diseases, autoimmune disorders and inflammatory disorders. The present invention further provides methods for screening and identifying lymphoid tissue inducing agents and / or immunomodulatory agents.

A preferably non-electrical nerve communication enhancement tool that sends specific, pre-timed, controlled vibrational and / or acoustical stimulation frequencies to the body to enhance nerve communication for the purpose of assisting in proper function of skeletal muscle, smooth muscle, sympathetic and parasympathetic nervous systems, and facilitating rapid and improved cerebellar timing circuit and related cerebellar learning mechanism pathways such as the inferior olivary-Purkinje-Thalamus cell system and other similar neuronal pools, to improve muscle memory, coordinated functional neuron-musculo-skeletal performance improvement, enhance blood flow, increased range of motion, flexibility, strength and dexterity, neuromuscular re-education, muscle tone recovery, pain modulation, improved eye-hand coordination, gait improvement, balance and stability gains, kinetic chain integration, neurological performance enhancement, sensory dysfunction reduction, and improvement in mental and cognitive function.

The invention provides a method for substantially reducing the size of a thrombus in a blood vessel in which blood is flowing. The method includes delivering a heat transfer element to a blood vessel in fluid communication with a thrombosed blood vessel. The temperature of the heat transfer element is adjusted such that the same is sufficient to remove heat from the flowing blood. Heat is transferred from a volume including the thrombus to the heat transfer element. In a separate embodiment, heat may be delivered to the volume including the thrombus from the heat transfer element. The resultant temperature of the volume may be sufficient to substantially reduce the size of a thrombus. For example, the resultant temperature of the volume may be sufficiently high to substantially enhance plasminogen activation near the thrombus. In a separate embodiment, a therapeutic drug may be delivered to the blood vessel to further reduce the size of a thrombus, the drug having an optimal temperature at the hypothermic or hyperthermic temperature of the blood.

A method and apparatus for stimulation of a baroreflex system of a patient is provided. A method comprises establishing a therapy regimen including at least one pulse which includes at least two phases. Each phase has a polarity which is different than that of the other phase. The baroreflex system of the patient is activated with at least one baroreflex activation device which is responsive to the therapy regimen.

Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.

Disclosed is a method for determining Idle mode Signaling Reduction (ISR) activation in a mobile communications system.When a mobility management node decides to activate an ISR feature in an IMS network environment where hetero mobile communications networks (e.g., E-UTRAN and UTRAN / GERAN) interwork with each other, considered are not only whether an ISR feature can be supported, and whether a UE can use IMS voice, but also conditions (information) on whether IMS voice over PS domain can be supported. This may allow a voice call transferred to the UE from the network to be delivered to a domain (PS or CS domain) selected with consideration of an access network state without delay.

A method for the treatment of obesity or other disorders by electrical activation or inhibition of the sympathetic nervous system is disclosed. This activation or inhibition can be accomplished by stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an electrode. This nerve activation can result in reduced food intake and increased energy expenditure.

Modular aAPCs and methods of their manufacture and use are provided. The modular aAPCs are constructed from polymeric microparticles. The aAPCs include encapsulated cytokines and coupling agents which modularly couple functional elements including T cell receptor activators, co-stimulatory molecules and adhesion molecules to the particle. The ability of these aAPCs to release cytokines in a controlled manner, coupled with their modular nature and ease of ligand attachment, results in an ideal, tunable APC capable of stimulating and expanding primary T cells.

The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules consisting of a tumor targeting moiety fused with one or more costimulatory molecules / chemokines / cytokines.

Setting up a user equipment (UE) device via a peer-to-peer wireless link. A peer device may be discovered using a peer-to-peer wireless communication protocol. A peer-to-peer wireless link may be established with the peer device using the peer-to-peer wireless communication protocol. Device setup information for the UE may be requested from the peer device via the peer-to-peer wireless link. The device setup information may be received from the peer device via the peer-to-peer wireless link. The UE may be configured using the device setup information.

This invention relates to antibodies and antigen binding fragments and conjugates containing same, and / or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.

The invention provides compositions and methods for treating HER2-postitive cancers. The method comprising administering a PD-1 axis binding antagonist and an antibody that targets HER2.